Carabrolactone B exhibits potential in pharmaceutical research due to its bioactive properties. It has shown antimicrobial activity against certain pathogenic bacteria, making it a candidate for development in anti-infective agents. Additionally, studies indicate moderate cytotoxic effects on specific cancer cell lines, suggesting possible use in oncology-related drug discovery. Its unique lactone structure also makes it a subject of interest in synthesizing derivatives for structure-activity relationship studies. Research remains in early stages, primarily in vitro, with potential for further exploration in therapeutic applications.